Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Blood - 28 Mar 2019

Esnault Cécile, Rahmé Ramy, Rice Kim L, Berthier Caroline, Gaillard Coline, Quentin Samuel, Maubert Anne-Lise, Kogan Scott, de Thé Hugues

Abstract excerpt

Acute promyelocytic leukemia (APL) is often associated with activating FLT3 signaling mutations. These are highly related to hyperleukocytosis, a major adverse risk factor with chemotherapy-based regimens. APL is a model for oncogene-targeted therapies: all-trans retinoic acid (ATRA) and arsenic both target and degrade its ProMyelocytic Leukemia/Retinoic Acid Receptor α (PML/RARA) driver. The combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Retinoids in leukemia and cellular processes

Source

Open in PubMed Open full text

Identifiers

PMID: 30674471
DOI: 10.1182/blood-2018-07-866095
PMCID: PMC6440296

Genes

PML
FLT3
RARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemiasPMID 30674471Read ↗

Acute promyelocytic leukemia, arsenic, and PML bodiesSemantic proximity Read ↗

ATRA Resistance in Acute Promyelocytic Leukemia: Mechanisms Unveiled, Therapies ReimaginedSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapiesSemantic proximity Read ↗

Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivoSemantic proximity Read ↗

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.Semantic proximity Read ↗

Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemiaSemantic proximity Read ↗

Differentiation therapy of acute myeloid leukemia: past, present and futureSemantic proximity Read ↗

PML/RARα and FLT3-ITD induce an APL-like disease in a mouse modelSemantic proximity Read ↗

How retinoic acid and arsenic transformed acute promyelocytic leukemia therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.